Abiologics is a startup. Brouky records 1 investor associated with the company.
Abiologics leverages artificial intelligence and chemical protein synthesis to create a new class of supranatural and programmable biologics called Synteins™, aimed at revolutionizing therapeutics across oncology, immunology, and metabolic diseases.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.